AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3623815 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic fenfluramine
Number of subjects: 5
Study 31420383 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitric oxide (NO) at 20 ppm administered into the CPB oxygenator for the duration of CPB
Number of subjects: 1320
Study 31420383 — intervention group
Group type: COMPARATOR
Intervention: Standard care (no NO)
Number of subjects: 1320
Study 31420383 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitric oxide (NO)
Number of subjects: 1320
Study 28117192 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy for PTSD
Number of subjects: 321
Study 25853743 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine manual thrombectomy
Number of subjects: 10732
Study 25853743 — intervention group
Group type: COMPARATOR
Intervention: PCI alone
Number of subjects: 10732
Study 23340885 — intervention group
Group type: EXPERIMENTAL
Intervention: myo-inositol plus 200 µg folic acid twice a day
Number of subjects: 110
Study 23340885 — intervention group
Group type: COMPARATOR
Intervention: Placebo (200 µg folic acid twice a day)
Number of subjects: 110
Study 21830396 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplement of 200kcal before endoscopic therapy (n=18)
Number of subjects: 36
Study 21830396 — intervention group
Group type: COMPARATOR
Intervention: No energy supplied (fasting group) before endoscopic therapy (n=18)
Number of subjects: 36
Study 19880429 — intervention group
Group type: EXPERIMENTAL
Intervention: MEN11420 2 mg
Number of subjects: 12
Study 19880429 — intervention group
Group type: EXPERIMENTAL
Intervention: MEN11420 8 mg
Number of subjects: 12
Study 19880429 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 19880429 — intervention group
Group type: EXPERIMENTAL
Intervention: MEN11420 (both doses)
Number of subjects: 12
Study 16309383 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial TNF-alpha infusion
Number of subjects: 95
Study 16309383 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 95
Study 15639689 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol LP 200 mg once daily
Number of subjects: 230
Study 15639689 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230
Study 11157012 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined-modality therapy (neoadjuvant chemotherapy with cyclophosphamide, doxorubicin, and fluorouracil or cyclophosphamide, doxorubicin, vincristine, and prednisone, followed by local therapy and radiotherapy)
Number of subjects: 70
Study 11157012 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined-modality therapy
Number of subjects: 70
Study 11157012 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy
Number of subjects: 70
Study 9766106 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoral fluoride-releasing system (IFRS)
Number of subjects: 0
Study 9766106 — intervention group
Group type: COMPARATOR
Intervention: 1.1 percent neutral sodium fluoride gel in custom trays (Control)
Number of subjects: 0
Study 7817812 — intervention group
Group type: EXPERIMENTAL
Intervention: ELISA for urinary deoxypyridinoline (Dpd)
Number of subjects: 402
Study 7817812 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Dpd by HPLC
Number of subjects: 402
Study 7817812 — intervention group
Group type: COMPARATOR
Intervention: Normal adults (healthy individuals)
Number of subjects: 402
Study 7817812 — intervention group
Group type: COMPARATOR
Intervention: Children (healthy individuals)
Number of subjects: 402
Study 3057063 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sclerotherapy (ES)
Number of subjects: 65
Study 3057063 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (P)
Number of subjects: 65
Study 31055729 — intervention group
Group type: EXPERIMENTAL
Intervention: Active information processing training (AIPT) (n = 49)
Number of subjects: 205
Study 31055729 — intervention group
Group type: COMPARATOR
Intervention: Post-control (n = 55)
Number of subjects: 205
Study 28454553 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory oxygen used during daily activities for a 2-week period at an optimal flow rate determined by titration at screening visit.
Number of subjects: 0
Study 28454553 — intervention group
Group type: COMPARATOR
Intervention: No ambulatory oxygen for a 2-week period.
Number of subjects: 0
Study 28454553 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory oxygen
Number of subjects: 0
Study 26408054 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention program (exercise program 3 days/week, 90 min sessions)
Number of subjects: 160
Study 26408054 — intervention group
Group type: COMPARATOR
Intervention: Family-based lifestyle and psycho-educational program (2 days/month)
Number of subjects: 160
Study 24308693 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingelvac PRRS MLV vaccine
Number of subjects: 120
Study 24308693 — intervention group
Group type: EXPERIMENTAL
Intervention: Amervac PRRS vaccine
Number of subjects: 120
Study 24308693 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrsvac‐183 vaccine
Number of subjects: 120
Study 24308693 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcilis PRRS vaccine
Number of subjects: 120
Study 24308693 — intervention group
Group type: COMPARATOR
Intervention: Mock vaccination (Control)
Number of subjects: 120
Study 21924624 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle vibration intervention (12×4 min daily at 100Hz, 0.3mm amplitude) during immobilization
Number of subjects: 30
Study 21924624 — intervention group
Group type: COMPARATOR
Intervention: Control group (ankle immobilization without vibration)
Number of subjects: 30
Study 19812508 — intervention group
Group type: EXPERIMENTAL
Intervention: Core Stabilization Exercise Program (CSEP)
Number of subjects: 2616
Study 19812508 — intervention group
Group type: COMPARATOR
Intervention: Traditional Exercise Program (TEP) with sit-ups
Number of subjects: 2616
Study 16696910 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuezhikang Capsules (ZXKC)
Number of subjects: 112
Study 16696910 — intervention group
Group type: COMPARATOR
Intervention: Probucol
Number of subjects: 112
Study 15002082 — intervention group
Group type: EXPERIMENTAL
Intervention: Nelfinavir (NFV)
Number of subjects: 775
Study 15002082 — intervention group
Group type: COMPARATOR
Intervention: Ritonavir (RTV)
Number of subjects: 775
Study 11697808 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/day of alendronate, 0.50 microg/day of calcitriol, and 500 mg/day of calcium carbonate
Number of subjects: 40
Study 11697808 — intervention group
Group type: COMPARATOR
Intervention: 0.50 microg/day of calcitriol and 500 mg/day of calcium carbonate
Number of subjects: 40
Study 9329411 — intervention group
Group type: EXPERIMENTAL
Intervention: Plastic tape
Number of subjects: 30
Study 9329411 — intervention group
Group type: EXPERIMENTAL
Intervention: Pectin barrier
Number of subjects: 30
Study 9329411 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophilic gel
Number of subjects: 30
Study 9329411 — intervention group
Group type: COMPARATOR
Intervention: Control (no adhesive)
Number of subjects: 30
Study 7608850 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanate potassium during the first 10 post-operative days
Number of subjects: 24
Study 7608850 — intervention group
Group type: COMPARATOR
Intervention: No antibiotics
Number of subjects: 24
Study 7608850 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24
Study 3043111 — intervention group
Group type: EXPERIMENTAL
Intervention: MCNU
Number of subjects: 77
Study 3043111 — intervention group
Group type: COMPARATOR
Intervention: Busulfan
Number of subjects: 77
Study 29143156 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants preferred greater social distance from a person with psychosis than a person with depression.
Number of subjects: 960
Study 29143156 — intervention group
Group type: EXPERIMENTAL
Intervention: Beliefs that PPSD were dangerous increased social distance.
Number of subjects: 960
Study 29143156 — intervention group
Group type: EXPERIMENTAL
Intervention: Familiarity with PPSD and belief in their recovery reduced social distance.
Number of subjects: 960
Study 28785895 — intervention group
Group type: EXPERIMENTAL
Intervention: TIVA or inhalational general anesthesia
Number of subjects: 59
Study 26206144 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual mammographic screening from age 40 years
Number of subjects: 160921
Study 26206144 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care (invited for screening at age 50 years and every 3 years thereafter)
Number of subjects: 160921
Study 24086114 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 755
Study 24086114 — intervention group
Group type: COMPARATOR
Intervention: Counselling
Number of subjects: 755
Study 24086114 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual Care
Number of subjects: 755
Study 20499061 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip resurfacing for rheumatoid arthritis
Number of subjects: 178
Study 20499061 — intervention group
Group type: COMPARATOR
Intervention: Osteoarthritis group
Number of subjects: 178
Study 19073976 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (600 mg per day)
Number of subjects: 1071
Study 19073976 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for aspirin group)
Number of subjects: 1071
Study 19073976 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistant starch (30 g per day)
Number of subjects: 1071
Study 19073976 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for resistant starch group)
Number of subjects: 1071
Study 22437997 — intervention group
Group type: EXPERIMENTAL
Intervention: ChloraPrep (2% chlorhexidine gluconate and 70% isopropyl alcohol)
Number of subjects: 100
Study 22437997 — intervention group
Group type: EXPERIMENTAL
Intervention: DuraPrep (0.7% available iodine and 74% isopropyl alcohol)
Number of subjects: 100
Study 22437997 — intervention group
Group type: COMPARATOR
Intervention: ChloraPrep
Number of subjects: 100
Study 22437997 — intervention group
Group type: COMPARATOR
Intervention: DuraPrep
Number of subjects: 100
Study 15662112 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral suspension of granisetron (2 mg) and dexamethasone (16 mg for highly emetogenic chemotherapy, 4 mg for moderately emetogenic chemotherapy)
Number of subjects: 43
Study 15662112 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life parameters
Number of subjects: 43
Study 12662126 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab 375 mg/m(2) intravenously once weekly for 4 weeks
Number of subjects: 399
Study 12662126 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab 375 mg/m(2) intravenously plus CHOP chemotherapy
Number of subjects: 399
Study 12662126 — intervention group
Group type: COMPARATOR
Intervention: Rituximab monotherapy
Number of subjects: 399
Study 10434816 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 75 mg
Number of subjects: 52
Study 10434816 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 300 mg
Number of subjects: 52
Study 10434816 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 7495042 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 345
Study 7495042 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 345
Study 7495042 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 345
Study 7495042 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 345
Study 2079176 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative modified MO and DO preparations with glass-ionomer liner
Number of subjects: 28
Study 2079176 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional MO and DO preparations with glass-ionomer liner
Number of subjects: 28
Study 2079176 — intervention group
Group type: COMPARATOR
Intervention: Conservative modified MO and DO preparations with calcium hydroxide liner
Number of subjects: 28
Study 2079176 — intervention group
Group type: COMPARATOR
Intervention: Conventional MO and DO preparations with calcium hydroxide liner
Number of subjects: 28
Study 381092 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine, 300 mg four times daily
Number of subjects: 27
Study 381092 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 12121503 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg b.i.d. with amoxicillin 500 mg t.i.d. and clarithromycin 200 mg t.i.d.
Number of subjects: 183
Study 12121503 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg b.i.d. with amoxicillin 500 mg t.i.d. and clarithromycin 200 mg t.i.d.
Number of subjects: 183
Study 12121503 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 10 mg b.i.d. with amoxicillin 500 mg t.i.d. and clarithromycin 200 mg t.i.d.
Number of subjects: 183
Study 12121503 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole regimen in homozygous extensive metabolizer genotype
Number of subjects: 183
Study 29482528 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (metformin + saxagliptin)
Number of subjects: 75
Study 29482528 — intervention group
Group type: COMPARATOR
Intervention: Saxagliptin monotherapy
Number of subjects: 75
Study 29482528 — intervention group
Group type: COMPARATOR
Intervention: Metformin monotherapy
Number of subjects: 75
Study 29482528 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin, metformin, and combination treatment
Number of subjects: 75
Study 29482528 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin and metformin treatments
Number of subjects: 75
Study 26772778 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-Controlled Ventilation (PCV)
Number of subjects: 52
Study 26772778 — intervention group
Group type: COMPARATOR
Intervention: Volume-Controlled Ventilation (VCV)
Number of subjects: 52
Study 26772778 — intervention group
Group type: EXPERIMENTAL
Intervention: Both VCV and PCV
Number of subjects: 52
Study 25415673 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented group (1mL of polymethylmethacrylate cement injected through the screw)
Number of subjects: 14
Study 25415673 — intervention group
Group type: COMPARATOR
Intervention: Nonaugmented group (no cement injection)
Number of subjects: 14
Study 22409966 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver nitrate cauterization
Number of subjects: 100
Study 22409966 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal antiseptic ointment (oxytetracycline hydrochloride‐polymyxin B sulfate)
Number of subjects: 100
Study 20032785 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir 300/100 mg once daily
Number of subjects: 883
Study 20032785 — intervention group
Group type: COMPARATOR
Intervention: Lopinavir/ritonavir 400/100 mg twice daily
Number of subjects: 883
Study 20032785 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir
Number of subjects: 883
Study 20032785 — intervention group
Group type: COMPARATOR
Intervention: Lopinavir/ritonavir
Number of subjects: 883
Study 19100932 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg of ondansetron (Group O)
Number of subjects: 150
Study 19100932 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg of ondansetron plus 20 mg of prochlorperazine (Group OP)
Number of subjects: 150
Study 19100932 — intervention group
Group type: COMPARATOR
Intervention: No antiemetic (Group C; control group)
Number of subjects: 150
Study 16837133 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS/LPS homozygotes
Number of subjects: 0
Study 16837133 — intervention group
Group type: EXPERIMENTAL
Intervention: APS/APS homozygotes
Number of subjects: 0
Study 16837133 — intervention group
Group type: EXPERIMENTAL
Intervention: APS/HPS heterozygotes
Number of subjects: 0
Study 16837133 — intervention group
Group type: EXPERIMENTAL
Intervention: val(158)met genotype
Number of subjects: 0
Study 16837133 — intervention group
Group type: EXPERIMENTAL
Intervention: COMT haplotypes
Number of subjects: 0
Study 16837133 — intervention group
Group type: COMPARATOR
Intervention: temporal summation of heat pain
Number of subjects: 0
Study 12771740 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracavernous injection of 20 mg prostaglandin E1 within the first 3 months (group 1)
Number of subjects: 73
Study 12771740 — intervention group
Group type: COMPARATOR
Intervention: Intracavernous injection of 20 mg prostaglandin E1 at 4 to 12 months (group 2)
Number of subjects: 73
Study 10758084 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized list method of recruitment
Number of subjects: 187
Study 10758084 — intervention group
Group type: COMPARATOR
Intervention: Manual recording method of recruitment
Number of subjects: 187
Study 8844449 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg three times a day for 7 days
Number of subjects: 12
Study 8844449 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1385902 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (Depo‐Medrol 80 mg/ml)
Number of subjects: 25
Study 1385902 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine (Marcaine .5% 1.5 ml)
Number of subjects: 25
Study 6734028 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 micrograms fenoterol by metered dose inhaler four times a day
Number of subjects: 8
Study 6734028 — intervention group
Group type: COMPARATOR
Intervention: No drug
Number of subjects: 8
Study 31352679 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic dose of low-molecular-weight heparin
Number of subjects: 1519
Study 31352679 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 1519
Study 31352679 — intervention group
Group type: EXPERIMENTAL
Intervention: L-TRiP(cast) score
Number of subjects: 1519
Study 29734920 — intervention group
Group type: EXPERIMENTAL
Intervention: Boston University approach to psychiatric rehabilitation
Number of subjects: 156
Study 29734920 — intervention group
Group type: COMPARATOR
Intervention: Generic approach to psychiatric rehabilitation
Number of subjects: 156
Study 26767612 — intervention group
Group type: EXPERIMENTAL
Intervention: Portion size increased to 200% of baseline amounts
Number of subjects: 48
Study 26767612 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-energy density foods
Number of subjects: 48
Study 26767612 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy density foods
Number of subjects: 48
Study 24812432 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec/insulin aspart (IDegAsp)
Number of subjects: 446
Study 24812432 — intervention group
Group type: COMPARATOR
Intervention: Biphasic insulin aspart 30 (BIAsp 30)
Number of subjects: 446
Study 22900989 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/day)
Number of subjects: 32
Study 22900989 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin (2 mg/day) for 6 months
Number of subjects: 32
Study 22900989 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in peripheral leukocyte count
Number of subjects: 32
Study 19858319 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal TPTD patch (20, 30, or 40-microg)
Number of subjects: 165
Study 19858319 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal TPTD 40-microg patch
Number of subjects: 165
Study 19858319 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups (including transdermal TPTD and TPTD injection)
Number of subjects: 165
Study 17661854 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg once daily (QD)
Number of subjects: 1139
Study 17661854 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg twice daily (BID)
Number of subjects: 1139
Study 17661854 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg QD
Number of subjects: 1139
Study 17661854 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg BID
Number of subjects: 1139
Study 17661854 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1139
Study 16109730 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupported reference arm
Number of subjects: 0
Study 16109730 — intervention group
Group type: COMPARATOR
Intervention: Supported reference arm
Number of subjects: 0
Study 16109730 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexion or extension conditioning of the reference arm
Number of subjects: 0
Study 16109730 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupported and weighted reference arm
Number of subjects: 0
Study 12592679 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen treatment (n = 24)
Number of subjects: 56
Study 12592679 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese nourishing Kidney herbs (CNKH) (n = 32)
Number of subjects: 56
Study 12592679 — intervention group
Group type: COMPARATOR
Intervention: Healthy women (control group)
Number of subjects: 56
Study 10080199 — intervention group
Group type: EXPERIMENTAL
Intervention: LASIK
Number of subjects: 33
Study 10080199 — intervention group
Group type: COMPARATOR
Intervention: PRK
Number of subjects: 33
Study 7593097 — intervention group
Group type: EXPERIMENTAL
Intervention: Core decompression
Number of subjects: 37
Study 7593097 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 37
Study 2179038 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetacaine topical anesthetic spray preparation
Number of subjects: 150
Study 2179038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 7363933 — intervention group
Group type: EXPERIMENTAL
Intervention: Disopyramide capsules 150 mg every 6 h for five days
Number of subjects: 10
Study 7363933 — intervention group
Group type: COMPARATOR
Intervention: Controlled-release tablets
Number of subjects: 10
Study 7363933 — intervention group
Group type: EXPERIMENTAL
Intervention: Disopyramide capsules
Number of subjects: 10
Study 31442618 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle and occupational exposures (including age, BMI, cigarette smoking, regular exercise, daily vehicle vibration)
Number of subjects: 644
Study 31442618 — intervention group
Group type: EXPERIMENTAL
Intervention: Univariate regression analyses
Number of subjects: 644
Study 31442618 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational loading measurements
Number of subjects: 644
Study 31442618 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate regression analyses
Number of subjects: 644
Study 31429418 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring (SM)
Number of subjects: 122